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Abstract: African-Americans have an increased risk of developing chronic and end-stage kidney 32 
disease, with much of it attributed to two common genetic variants in the APOL1 gene, termed G1 33 
and G2. Direct evidence demonstrating that these APOL1 risk alleles are pathogenic is still lacking 34 
as the APOL1 gene is only present in some primates and humans; thus experimental proof of 35 
causality of these risk alleles for renal disease has been challenging. Here, we generated mice with 36 
podocyte-specific inducible expression of the APOL1 reference allele (termed G0) or each of the risk 37 
alleles (G1 or G2). We show that mice with podocyte-specific expression of either APOL1 risk allele, 38 
but not the G0 allele, develop functional (albuminuria, azotemia), structural (foot process effacement 39 
and glomerulosclerosis) and molecular (gene expression) changes that closely resemble the human 40 
kidney disease. Disease development was cell-type specific, and likely reversible, and the severity 41 
correlated with the level of expression of the risk allele. We further found that expression of the 42 
APOL1 risk alleles interferes with endosomal trafficking and blocks autophagic flux, leading 43 
ultimately to inflammatory-mediated podocyte death and glomerular scarring. In summary, this is 44 
the first in vivo demonstration that expression of APOL1 risk alleles are causal for altered podocyte 45 
function and glomerular disease.  46 
  47 
  48 
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Introduction 49 
African-Americans have a 3-5-fold increased risk of developing chronic kidney disease 50 
(CKD) and end-stage renal disease (ESRD)1,2. Recent studies indicate that coding region variants 51 
(G1 and G2) in the apolipoproteinL1 (APOL1) gene explain much of this excess risk3,4. APOL1 52 
variants contribute to about 70% of non-diabetic ESRD (up to 40% of all ESRD) in African-53 
Americans, and are associated with focal segmental glomerulosclerosis (FSGS), hypertension-54 
attributed ESRD and HIV associated nephropathy (HIVAN) with odds ratios of 17, 7.3 and 29, 55 
respectively5. Unlike most disease-associated high penetrant variants the G1 and G2 alleles are 56 
present in the general population with a relatively high allele frequency6-8. It appears that these 57 
variants emerged as a result of a positive selection, as they protect against African sleeping sickness, 58 
caused by the parasite Trypanosoma brucei rhodesiense8. APOL1 functions as a component of the 59 
trypanolytic factor. It is taken up by the parasite, incorporates into endosomal membranes and 60 
transits to the lysosome. The low lysosomal pH induces a conformational change in the protein and 61 
it forms a pore-forming channel. The resulting ion transport causes osmotic lysosomal swelling and 62 
parasite death. The reference (G0) APOL1variant has lost its trypanolytic function in 63 
T.b.rhodesiense due to the emergence of a trypanosomal protein (serum resistance associated; SRA) 64 
that binds to and neutralizes the activity of APOL1 protein9. APOL1 risk variants (G1 and G2) have 65 
decreased affinity to SRA, and are able to lyse T.b.rhodesiense subspecies4. 66 
Surprisingly, even six years after the discovery of this genetic association, very little is 67 
known about the functional role of APOL1 variants in kidney disease development. Proof of concept 68 
experiments, using animal models demonstrating that APOL1 G1 (double missense mutations) and 69 
G2 (an indel) polymorphisms are causal mutations for kidney disease are lacking, and indeed some 70 
recent studies failed to recapitulate kidney disease in animals expressing one of risk alleles10. Some 71 
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of the key barriers have been that mice and other model organisms lack the APOL1 gene. In humans, 72 
APOL1 expression does not show tissue specificity, making it difficult to identify the cell type 73 
critical for renal disease development11. Furthermore, the variant is seemingly associated with 74 
diverse clinical phenotypes, including hypertensive nephrosclerosis, FSGS, HIVAN and lupus 75 
nephritis12. Recent pathological studies indicate increased incidence of solidified-type global 76 
sclerosis in subjects with high-risk APOL1 genotypes compared to people with kidney disease who 77 
carry the reference allele13-15. Observational cohort studies show that high-risk genotype subjects 78 
have higher albuminuria and faster GFR decline16-18.  79 
The goal of this study was to answer the question whether kidney-specific expression of 80 
APOL1-G1 and G2 variants causes kidney disease. To address this issue we generated a new mouse 81 
model with conditional and inducible expression of APOL1 reference (G0) and risk alleles (G1, G2). 82 
We found that podocyte-specific expression of APOL1 risk alleles, but not the G0 allele, causes 83 
severe albuminuria and glomerulosclerosis. We show that this model recapitulates features of the 84 
human phenotype at functional, structural and molecular levels, indicating that the G1 and G2 85 
variants are disease- causing alleles. On the mechanistic level we show that APOL1 mostly resides 86 
in the late endosomal compartment and risk variants show altered vesicular trafficking, decreased 87 
autophagic flux and shifting of cells to an inflammatory death pathway. 88 
 89 
 90 
 91 
Results 92 
 93 
Podocyte-specific expression of G1 or G2 in mice leads to kidney disease  94 
We used the doxycycline inducible (rtTA) system (Fig. 1a) to generate mice with podocyte-95 
specific conditionally inducible APOL1 expression under doxycycline control. Using this transgenic 96 
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system we expressed GFP and either the APOL1 reference allele (G0) or one of the two risk alleles 97 
(G1 or G2) (Supplementary Fig. 1) from a bicistronic promoter (TRE-GFP/APOL1). We used the 98 
nephrin (NPHS1) rtTA promoter to drive podocyte-specific expression. Successful transgene 99 
expression following doxycycline administration was confirmed by immunohistochemistry (Fig. 1a). 100 
We identified at least three founders from each transgenic line that produced offspring expressing 101 
APOL1 and GFP transcripts and proteins. Male littermates of these founders were used for all 102 
further analysis. Double transgenic mice (NPHS1-rtTA/TRE-APOL1) are called transgenic mice and 103 
single transgenic mice (TRE-APOL1) are controls.  104 
Littermates of double and single transgenic mice were placed on doxycycline diet at 3.5 105 
weeks of age. Risk allele transgenic mice developed significant proteinuria as early as three weeks 106 
after doxycycline diet induction (data not shown). Both risk allele transgenic mice (NPHS1-107 
rtTA/TRE-APOL1-G1 and NPHS1-rtTA/TRE-APOL1-G2) had significantly higher mean urinary 108 
albumin to creatinine ratio (ACR) compared to reference allele transgenic mice (NPHS1-rtTA/TRE-109 
APOL1-G0) (Fig. 1b). Kidney functional analysis, including measurements of serum blood urea 110 
nitrogen (BUN) and serum creatinine, showed that mice expressing the G2 risk allele had significant 111 
azotemia compared to control (wild type) mice  (Fig. 1c). The significant azotemia likely contributed 112 
to the greater mortality observed in G2 risk allele expressing mice compared to mice expressing 113 
reference (G0) allele  (Supplementary Fig. 2a).  114 
Structural examination performed by light microscopy analysis of PAS-stained kidney 115 
sections indicated increased global and segmental glomerulosclerosis in mice expressing either 116 
APOL1 risk allele (Fig. 1d). By three weeks after doxycycline induction G1 and G2 transgenic mice 117 
developed severe global (solidified-type) and segmental sclerosis compared to G0 control mice (Fig. 118 
1e). Ultrastructural analysis using transmission electron microscopy (EM) showed increased foot 119 
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process effacement, which is an important ultrastructural characteristic of proteinuric 120 
glomerulopathies in patients, in mice expressing a risk allele compared to those expressing the 121 
reference allele (Fig. 1f).  122 
Next we performed molecular analysis of the NPHS1-rtTA/TRE-APOL1 mouse model by 123 
performing RNA-seq of whole kidneys from control, reference and risk allele mice (Supplementary 124 
Fig. 2b). This unbiased analysis identified many differentially expressed genes (Supplementary 125 
Table 1). We used gene set enrichment analysis to identify key pathways driving these 126 
transcriptional changes (Fig. 1g). The top differentially expressed pathways include JAK-STAT 127 
signaling, cytokine-cytokine receptor interaction and phagosome related genes indicated a potential 128 
connection between APOL1-associated kidney disease and immunity19 (Fig. 1g, Supplementary 129 
Fig. 2c and Supplementary Table 2). We have also examined the expression of five genes reported 130 
to be differentially expressed when patients with nephrotic syndrome with low- and high-risk 131 
APOL1 allele status were compared20. Except for one human-specific gene (SNORA14), all four 132 
genes that are present in mice showed increased expression in the mouse model (Fig. 1h) and 133 
statistical correlation with glomerulosclerosis (Supplementary Table 3).  134 
 135 
G1 and G2 phenotypes are cell type-and dose-dependent 136 
To show that the renal phenotype development after induced expression of G1 or G2 is not 137 
due to non-specific toxicity, we generated mice with tubule-specific expression of APOL1 by 138 
crossing the TRE-APOL1 transgenic mice with Pax8-rtTA mice. We confirmed transgene 139 
expression in the Pax8-rtTA/TRE-APOL1-G0 and Pax8-rtTA/TRE-APOL1-G1 mice by 140 
immunostaining (Supplementary Fig. 3a) and Western blotting (Supplementary Fig. 3b). Further, 141 
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we performed structural analysis by PAS staining of mouse kidney sections and found no observable 142 
alterations in mice expressing risk allele APOL1 (Supplementary Fig. 3a). Serum creatinine, BUN, 143 
and urinary ACR measurements indicated no functional alterations in tubule-specific transgenic 144 
mice (Supplementary Fig. 3c). Furthermore transcript level analysis for kidney injury markers 145 
Kim1 and Col4a (by qRT-PCR) showed no significant differences among control mice and those 146 
expressing the G0, G1 or G2 alleles (Supplementary Fig. 3d).  147 
To further show that disease development in podocytes specifically depends on the 148 
presence of the risk variants, we identified mice with equal expression of G0, G1 and G2 APOL1 149 
in podocytes and examined their phenotype (Fig. 2a,b). In mice with equal expression of G0, G1 or 150 
G2, those with G1 and G2 variants had significantly higher albuminuria, indicated by the higher 151 
ACR level, compared to those with the G0 reference allele (P = 0.0029 and 0.0061, respectively) 152 
(Fig. 2b). Similarly, in vitro studies show that G1 and G2 APOL1 variants expressed in transfected 153 
HEK293 cells at the same level as G0 variant were associated with increased cytotoxicity compared 154 
to G0-APOL1 transfected cells (Fig. 2c). These findings are recapitulated in human samples 155 
(Supplementary Table 4). When glomerular expression of APOL1 was matched in low- and high-156 
genetic risk samples, high-risk samples had significantly lower eGFR (P = 0.032) (Fig. 2d). In 157 
summary, the phenotype in mice and human subjects as well as the cytotoxicity in vitro is closely 158 
linked to the risk variants supporting the notion that disease development is not a result of broad 159 
cytotoxicity.  160 
 As APOL1 genetic variants represent a complex trait, not all human subjects and not all mice 161 
develop severe kidney disease. To understand the variation in disease severity, first we correlated 162 
APOL1 transcript levels with kidney functional changes. We found a strong linear correlation 163 
between APOL1 transcript levels and albuminuria in mice with G1 and G2 podocyte-specific 164 
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expression, whereas no matter the expression level of the G0 allele we did not observe albuminuria 165 
(Fig. 2e). Similarly to albuminuria, histological damage was more severe in mice expressing higher 166 
levels of risk allele APOL1 compared to mice expressing the same risk allele at a lower level (Fig. 167 
2f). Further, we inducibly expressed either a control vector, or one expressing either G0, G1 or G2 in 168 
transfected HEK293 cells using the doxycycline expression system we used in vivo. We found under 169 
escalating doses of doxycycline only expression of G1 or G2 at the highest doses resulted in greater 170 
cytotoxicity compared to cells expressing the G0 reference allele or a control vector, suggesting that 171 
G1 and G2 toxicity is dose dependent (Fig. 2g).  172 
To understand whether the renal disease phenotype in patients also depends on APOL1 levels, 173 
we compared APOL1 transcript levels in glomeruli isolated from 286 human kidney samples. Patient 174 
characteristics are shown in Supplementary Table 4. We found that APOL1 transcript level 175 
(regardless of genotype) is significantly higher in glomeruli isolated from CKD kidneys (GFR < 60) 176 
compared to controls (GFR>60) (P = 0.000283) (Fig. 2h). This was true even when diabetic samples 177 
were excluded (Supplementary Fig. 4a). Furthermore we have also examined the correlation 178 
between glomerular APOL1 levels and GFR in low- and high-risk samples. APOL1 levels are higher 179 
in lower GFR samples both in low- and high-risk samples (Supplementary Fig. 4b). This 180 
relationship is much stronger in high-risk samples (Fig. 2d) when compared to low risk samples, just 181 
as we observed in our mouse model (Fig. 2e). 182 
Our studies also indicated that interferon is a strong regulator of APOL1 levels both in low- 183 
and high-risk human podocytes (Supplementary Fig. 4c). We detected a strong statistically 184 
significant correlation between STAT1 and APOL1 transcript levels in human glomeruli (P < 2.2e-185 
16) (Supplementary Fig. 4d) and found that STAT1 binds to APOL1 enhancers (Supplementary 186 
Fig. 4e). 187 
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Given the strong correlation between APOL1 levels and phenotype development we also 188 
examined whether turning APOL1 expression off in our mouse model would lessen disease severity. 189 
We placed mice on doxycycline-containing food for 14 days and either kept the mice on doxycycline 190 
or took them off the diet for 7 (at day 21) or 17 (at day 31) days. The decrease we observed in 191 
albuminuria by Coomassie-stained gels of urine samples when doxycycline treatment was halted 192 
indicates that albuminuria development strongly correlates with the expression of risk allele APOL1 193 
in podocytes (Fig 2i).  194 
 195 
 A role of APOL1 in autophagic flux  196 
Next, we examined the molecular mechanism of APOL1 variant-induced kidney disease. 197 
Immunogold electron micrographs of human kidney tissue samples showed that APOL1 localized to 198 
the plasma membrane and associated intracellular vesicles in podocytes (Fig. 3a). We used 199 
intracellular compartment-specific markers to determine APOL1 localization in cultured human 200 
podocytes. We found co-localization of APOL1 with early endosomal marker EEA1 and late 201 
endosomal marker Rab7 (Fig. 3b,c). There was minimal colocalization with the recycling endosomal 202 
marker Rab11, the autophagic vacuole marker LC3, the lysosomal marker LAMP2 (Fig. 3b,c), the 203 
Golgi marker GM130, the ER marker calnexin or the lipid droplet marker perilipin2 204 
(Supplementary Fig. 5). Examination of GFP-APOL1 and RFP-Rab7 localization in transfected 205 
HEK293 cells further confirmed that APOL1 resides in the late endosomal compartment (Fig. 3d 206 
and Supplementary Video 1).  207 
 We noted that expression of APOL1 in HEK293 cells using the TRE-APOL1 constructs 208 
(Supplementary Fig. 1) resulted in excessive accumulation of intracellular vesicles, which was 209 
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more evident in the G1 and G2 variant cells compared to G0 controls (Supplementary Fig. 6a). 210 
Immunofluorescence studies in human podocytes from low risk (G0/G0) and high-risk allele 211 
subjects (G1/G2) indicated an increase in Rab7 (late endosome) (Fig. 3e) and LC3II 212 
(autophagosomes) (Fig. 3f) -positive intracellular organelles in the high-risk allele podocytes 213 
compared to low-risk allele podocytes. Similarly, there was an increase in total Rab7, Rab11 and 214 
steady state LC3II protein levels in APOL1 risk allele transfected HEK293 cells compared to 215 
reference allele transfected cells (Supplementary Fig. 6b,c). Transmission EM of APOL1 risk allele 216 
transfected cells indicated accumulation of different types of vesicles, including multivesicular 217 
bodies (MVB; also called late endosomes) and autophagic compartments compared to reference 218 
allele transfected cells (Fig. 3g-i). Analysis of the morphometric characteristics of the autophagic 219 
vacuoles revealed a significantly higher abundance of autophagosomes (APG or AP; double 220 
membrane vesicles with content of similar characteristics to the surrounding cytosol) and a decrease 221 
in autolysosome fraction (AUT or AL; single membrane vacuoles with cargo in an advanced stage of 222 
degradation) in high risk allele-transfected cells compared to that in G0 or control cells (Fig. 3h,i). 223 
In addition, we noticed an expansion of vesicular compartments compatible with amphisomes 224 
(AMP; resulting from the fusion of autophagosomes and MVB; and containing cytosolic material as 225 
well as multiple small vesicles); the size and frequency of this was even more abundant in cells 226 
transfected with APOL1 risk alleles compared to reference allele transfected cells (Fig. 3i). 227 
Immunofluorescence and confocal spinning disk microscopy showed increased colocalization of 228 
APOL1 risk variants with late (Rab7 positive) and recycling (Rab11 positive) endocytic 229 
compartments in transfected HEK293 cells (Fig. 3j, Supplementary Fig. 6d,e and Supplementary 230 
Video 2a,b).  231 
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To further characterize the APOL1-induced intracellular vesicle defect, we next examined 232 
autophagy, as there is a very dynamic interplay between autophagic and endocytic compartments 233 
under physiologic conditions. Furthermore, previous studies have proposed that APOL1 plays a role 234 
in autophagy21. First, we quantified the extent of autophagic vacuoles in reference and risk allele 235 
transfected HEK293 cells estimated by conjugated LC3 (LC3II) (Fig. 4a). In agreement with the 236 
immunofluorescence and EM data, we found that at baseline there was a greater amount of LC3II in 237 
cells expressing a risk allele compared to cells expressing reference allele (Fig. 4a).  238 
Increased LC3II can result from either increased autophagosome biogenesis or a blockage of 239 
autophagosome clearance. In order to distinguish between these possibilities, we examined 240 
autophagic vacuole content (amount of autophagic vesicles, represented by LC3II level in baseline 241 
conditions) and autophagic flux (lysosomal fusion and degradation of autophagic cargo, represented 242 
by the degree of increase in LC3II after pharmacological blockage of lysosomal degradation) (Fig. 243 
4b). We speculated that the greater LC3II content associated with risk allele (G1 or G2) expression  244 
was likely a consequence of lower autophagic flux (and degradation of LC3II). We calculated the 245 
autophagic flux by blocking the lysosomal degradation of LC3 and demonstrated a lower degree of 246 
autophagic flux in risk allele-transfected HEK293 cells (compared to G0 allele expressing cells) (Fig. 247 
4b). Analysis of transmission EM studies further confirmed that risk allele-transfected cells 248 
contained a greater amount of autophagic vacuoles (AP) but fewer autolysosomes (AL) compared to 249 
reference allele transfected cells indicating a blockage in autophagic flux (Fig. 3g and Fig. 4c).  250 
To examine the relevance of these findings to the human condition we analyzed low-risk 251 
(G0/G0) and high-risk (G1/G2) human podocytes. These cells presented with a similar defect in 252 
autophagy; G1/G2 cells showed greater numbers of autophagic vacuoles at baseline, but defects in 253 
autophagic flux compared to G0/G0 cells  (Fig. 4d,e).   254 
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 255 
APOL1 regulates the acidification of endocytic vesicles 256 
Next we further analyzed the nature of the autophagic flux defect. A lysosomal defect would 257 
manifest as a defect in autolysosome formation (or reduced autophagic flux) therefore we first 258 
analyzed lysosomes in control- and risk allele-expressing cells. LysoTracker analysis of reference 259 
and risk allele-transfected HEK293 cells did not show significant differences in lysosomal content or  260 
acidification (Supplementary Fig. 7a). Identical results were seen in human podocytes harboring 261 
low- or high-risk alleles (Supplementary Fig. 7b), ruling out a gross defect in lysosomal function.  262 
The most likely explanation to synthesize these results is that APOL1 risk alleles interfere 263 
with lysosomal fusion with autophagosomes. We examined the colocalization of the lysosomal 264 
SNARE protein VAMP822 with two autophagosome markers Stx17 (Supplementary Fig. 7c,d) and 265 
LC3II (Supplementary Fig. 7e,f). We found a decrease in colocalization between VAMP8 and both 266 
Stx17 and LC3II in APOL1-G1 and G2 risk allele transfected HeLa cells. These studies further 267 
support a defect in autophagosome maturation. 268 
Many cells respond to reduced fusion of autophagosomes with the lysosome by increasing 269 
the fusion of autophagosomes directly with the endosome (resulting in amphisomes). To further 270 
characterize the endocytic compartment in APOL1 transfected cells, we analyzed the uptake of 271 
fluorescently labeled 10 kDa dextran in transfected HEK293 cells. In agreement with the EM data, 272 
cells expressing APOL1 risk alleles displayed a significant increase in the amount of endocytic 273 
vesicles compared to cells expressing the G0 reference allele (Supplementary Fig. 7g,h). We also 274 
examined endosomal pH using a 10 kDa dextran labeled with a pH sensitive dye (pHrodo). This dye 275 
reaches acidic compartments by endocytosis, in contrast to LysoTracker, that freely permeates 276 
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membranes to reach cellular acid compartments (Supplementary Fig. 7g). We found that the 277 
acidification of the endosomes was defective in risk allele transfected HeLa cells (Supplementary 278 
Fig. 7i), as the ratio of fluorescence between pHrodo and labeled dextran was lower in APOL1 risk 279 
allele cells compared to G0 transfected HeLa cells. These studies indicate that in the presence of 280 
APOL1 risk alleles there is a defect in autophagosome maturation, likely resulting from diminished 281 
lysosomal fusion and impaired acidification of the late endocytic compartment, thus most likely 282 
resulting in a defect in autophagy flux. This defect in autophagy raises the possibility that APOL1 283 
risk variant was not degraded and therefore accumulates in cells. However, our experiments 284 
indicated that this was not the case as APOL1 expression was generally slightly lower in risk allele 285 
cells when compared to reference allele transfected HEK293 cells (Supplementary Fig. 7j). 286 
 287 
APOL1 variants result in inflammatory cell death (pyroptosis)  288 
Podocyte loss due to cell death plays a critical role in the development of FSGS23,24; a 289 
common histological manifestation of APOL1-associated kidney disease. Upon examining the 290 
mechanism of APOL1-induced cytotoxicity, we failed to observe any increase in apoptosis in 291 
APOL1 risk allele-transfected cells (Fig. 5a). We therefore turned our attention to inflammatory cell 292 
death mechanisms as it has been shown that defect in non-inflammatory cell death can shift towards 293 
inflammatory cell death pathways including pyroptosis25,26. We found that cleaved caspase1, the key 294 
player in pyroptosis, was increased in APOL1 transfected cells. This was particularly pronounced in 295 
cells expressing the APOL1 risk alleles (Fig. 5b).  In pyroptosis active caspase1 cleaves interleukin 296 
1β (IL1β) into a mature and active protein that eventually leaks out of the cell. We found that the 297 
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level of mature IL1β was increased in the medium of cells expressing APOL1 risk allele compared 298 
to reference allele transfected cells (Fig. 5b).  299 
To prove that pyroptosis contributes to APOL1 risk allele-induced toxicity we treated cells 300 
with caspase1-specific inhibitors Ac-YVAD-CHO and VX765 and found that APOL1 risk allele-301 
induced cytotoxicity was significantly reduced (Fig. 5c). NLRP3 is a component of the 302 
inflammasome that activates caspase1 during pyroptosis. CRID3 and Parthenolide, as NLRP3 303 
inhibitors, also reduced APOL1 risk allele-induced cytotoxicity (Fig. 5d). In line with our hypothesis 304 
that defective autophagy is the critical inducer of pyroptosis, we found that autophagy inducers 305 
rapamycin (an mTOR inhibitor)27 and STF66247 decreased the APOL1-induced cytotoxicity (Fig. 306 
5d).  307 
 308 
Risk alleles increase inflammatory cell death in mice  309 
As our in vitro data suggested an inflammatory cell death in risk allele-expressing cells, we 310 
examined whether such a mechanism contributes to podocyte pathology in risk allele-expressing 311 
transgenic mice. We found a marked reduction in podocyte number in risk allele transgenic mice 312 
(Fig. 6a,b) and severe podocyte dedifferentiation indicated by decreased staining of nephrin in risk 313 
allele mice (Fig. 6a). DNA fragmentation, evident by TUNEL staining was increased in APOL1 risk 314 
allele mice (Fig. 6a, b), indicating severe podocyte injury and death. 315 
Next we examined whether an autophagy defect similar to the one we observed in vitro, can 316 
be detected in vivo in mice expressing either the APOL1 reference or one of the risk alleles. 317 
Transmission EM indicated a greater number of multivesicular bodies/amphisomes and 318 
autophagosomes in risk allele mice compared to G0 mice (Fig. 6c). The autophagosome (AP) to 319 
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autolysosome (AL) ratio was greater in mice expressing APOL1 risk allele in podocytes compared to 320 
G0 mice (Fig. 6d). Similarly to our in vitro finding, LC3II staining was greater in APOL1 risk allele 321 
mice compared to G0 mice (Fig. 6e).  322 
To further analyze the cell death mechanism in vivo, we focused on pyroptosis. We detected 323 
signs of greater inflammatory death in mice with podocyte-specific deletion of Atg7 324 
(NPHS2creAtg7flox/flox), the gatekeeper of autophagy as  IL1β and NLRP3 expression was greater 325 
in Atg7-deleted mice podocytes compared to single transgenic controls (Supplementary Fig. 8), 326 
pointing towards a link between decreased autophagy and increased pyroptosis in vivo. In mice with 327 
podocyte-specific expression of APOL1, immunostaining for IL1β, NLRP3 and caspase1 showed 328 
greater protein expression in kidney sections of risk allele transgenic mice compared to those 329 
expressing the reference allele (Fig. 6f-h), while we did not detect active caspase3 activity in risk 330 
allele mice (Fig. 6i). RNA-seq-based unbiased analysis indicated that caspase1, IL1β and NLRP3 331 
were greater in expression when risk allele mice were compared to reference allele and control mice 332 
(Fig. 6i).  333 
  334 
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Discussion 335 
G1 and G2 APOL1 variants have been strongly and reproducibly associated with kidney 336 
disease in patients. With the advent of whole genome and whole exome sequencing hundreds of 337 
disease-associated variants have been identified, but animal model experiments represent the 338 
mainstay of distinguishing causality from association in human genetics. Here we generated a mouse 339 
model with podocyte-specific inducible expression of APOL1 reference and risk variants. We show 340 
that risk variants recapitulate critical features of the human condition indicating that these variants 341 
are not only disease associated but indeed disease causing. Functional changes, such as albuminuria 342 
and azotemia present in the risk allele-expressing transgenic mice are consistently observed in 343 
patients. Structural changes in the mouse model include foot process effacement and mostly 344 
solidified-type global sclerosis with some segmental sclerosis and tubulointerstitial fibrosis. While 345 
further human studies are needed, recent observations indicated that increased solidified-type global 346 
sclerosis and more severe tubulointerstitial fibrosis distinguishes subjects with high-risk APOL1 347 
variants from subjects with low-risk genotypes13,14. Our mouse model studies here indicate that this 348 
lesion could represent an APOL1-specific phenotype that is superimposed on other CKD etiologies, 349 
such as hypertension, HIV or lupus (thus contributing to the seemingly variable phenotype of 350 
APOL1 kidney disease in humans). Moreover, APOL1 risk variant could act as a disease 351 
accelerating mechanism by inducing global glomerulosclerosis. The phenotype development in the 352 
mouse model not only closely resembled the human condition, but we found it was cell type and 353 
genotype restricted, indicating specific rather than non-specific toxicity.  354 
Our results also strongly indicate that phenotype development not only depends on the 355 
presence of G1 and G2 risk variants, but also on risk variant expression levels. The correlation 356 
between APOL1 G1 or G2 levels and disease severity was also observed in human glomerular 357 
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samples obtained from a large and diverse patient population. It is also in line with publications 358 
indicating that interferon (IFN) injection can lead to disease development in high-risk subjects28. 359 
Interferon seems to be a strong regulator of APOL1 expression and in human subjects STAT1 shows 360 
a remarkable correlation with APOL1 levels. We found that interferon increases cytotoxicity in high 361 
risk cells but its effect is not additive to the transgenic overexpression of APOL1. We therefore 362 
suggest that the level of APOL1-G1 and G2 represents a "second hit"; once risk variant APOL1 level 363 
rises above a critical threshold, disease develops (Supplementary Fig. 9). Besides the regular gene 364 
expression cues, environmental triggers, such as interferon treatment or infection, increase APOL1 365 
risk allele expression in kidney podocytes, which subsequently blocks autophagy and activates 366 
caspase1-mediated inflammatory cell death (pyroptosis), resulting in disease progression. The 367 
recessive mode of inheritance is also in line with the “threshold” hypothesis, as heterozygous 368 
subjects have an average of 50% risk variant levels that is less likely to reach a critical threshold in 369 
geographical areas where the “environmental trigger” is less strong. A recent publication indicates 370 
that in Sub-Saharan Africa, where both APOL1 risk variants and HIV incidence is much higher, 371 
even heterozygous individuals have a statistically significant increased disease risk29.  372 
Recently a mouse model with podocyte-specific non-inducible expression of either G0 or 373 
G2-APOL1 was published10. The authors have described pre-eclampsia but no glomerulosclerosis in 374 
this model, which seems to be different from the human phenotype. In this model APOL1 expression 375 
was significantly lower in risk allele mice. Given our results in this study that the kidney phenotype 376 
is strongly associated with APOL1 levels, this lower expression level might have played a role in the 377 
lack of observed renal disease. APOL1 expression in this model is constitutive, potentially causing a 378 
selective pressure and decreasing toxicity. Speaking to this issue in the pre-eclampsia model, the 379 
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authors have obtained significantly fewer founders for the risk allele than for the reference allele 380 
mice. The conditional inducible expression system we used here likely circumvented such problems.  381 
On the mechanistic level, APOL1 interferes with intracellular vesicle trafficking by 382 
disrupting autophagosome maturation, leading instead to expansion of mixed endocytic/autophagic 383 
compartments. The molecular mechanism whereby APOL1 affects autophagy and vesicular 384 
trafficking is not fully understood. We have found that acidification of endocytic vesicles was 385 
altered in cells expressing one of the risk alleles. Although dissipation of acidic endosomal pH could 386 
be secondary to rerouting of autophagosomes towards fusion with endosomes instead of lysosomes, 387 
the most likely explanation for this defect is that APOL1 acts as an ion channel in vesicles. 388 
Acidification of vesicles occurs by the action of a vacuolar ATPase, an electrogenic process; 389 
therefore an ion channel is needed to compensate the electric changes. APOL1 has been shown to 390 
function as an ion channel in lipid bilayers30, and therefore it is possible that it also functions as such 391 
in podocytes. Other possible mechanisms include a potential interaction of APOL1 with a GTPase or 392 
a SNARE protein, which would interfere with autophagosome maturation and lysosomal fusion. 393 
Future studies are needed to distinguish between these or other possibilities.  394 
We show that the effect of APOL1 on endocytic/autophagic maturation results in lower 395 
autophagic flux in cells expressing one of the APOL1 risk alleles. It has been suggested that 396 
autophagy is induced by APOL1, as it has a BH3 domain, and BH3-only proteins and BH3 mimetics 397 
induce autophagy through beclin-1 and the class III phosphorinositide3-kinase complex21,31. Also, 398 
both reference and risk alleles of APOL1 increase LC3II levels, yet autophagic flux was not 399 
specifically investigated in these studies32-34. Although induction of autophagosome formation could 400 
be in part responsible for the higher number of autophagosomes observed in cells expressing a 401 
APOL1 risk allele, our studies support the conclusion that most of the increase in steady state levels 402 
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of autophagosomes is due to reduced autophagic flux (lysosomal fusion and degradation of 403 
autophagic cargo). Podocytes, like other terminally differentiated cells, such as neurons, have high 404 
basal autophagy rates and autophagy is known to play an important role in podocyte homeostasis35.. 405 
Indeed, defects in autophagy in podocytes have been shown to induce podocyte loss, focal segmental 406 
glomerulosclerosis and proteinuria36-39.  407 
Our results indicate that this defect in autophagy and endocytic trafficking is associated with 408 
inflammatory cell death. Caspase1 and IL1β play a key role in APOL1-induced cytotoxicity. These 409 
results offer new therapeutic possibilities for APOL1-associated kidney disease with already 410 
approved IL-1 inhibitors or other inflammatory cell death inhibitors40,41. Given that caspase1 knock-411 
out animals develop normally42, this pathway is potentially targetable.  412 
Importantly, it seems that a positive feedback regulatory loop exists between APOL1 and 413 
inflammatory pathways. While APOL1 is part of the innate immune system and is strongly regulated 414 
by inflammatory cytokines; its expression results in inflammatory cell death21. Cytokines released 415 
following cell death can up-regulate APOL1 levels leading to further death. This regulatory loop 416 
likely explains the toxicity associated with APOL1 expression in vitro and in vivo. It may also 417 
explain the additive effect of HIV and APOL1 risk allele on glomerulosclerosis development, in 418 
light of the cytokine inducing effect of HIV and the potential additive activation of pyroptosis by the 419 
virus43,44. 420 
In summary we show that expression of either APOL1 risk allele in podocytes causes lesions 421 
that recapitulate the human APOL1-associated kidney disease at the functional, structural and 422 
molecular levels, thus proving that these variants are disease-causing mutations. Targeting these 423 
variants may reduce the increased kidney disease risk among millions of people of African descent.  424 
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Figure legends 563 
 Figure 1 Generation of a mouse model with cell-type-specific inducible expression of APOL1 564 
variants. (a) Upper: schematic representation of mouse model generation. Lower: representative 565 
images  of GFP immunostaining. (n = 15 per line) Scale bars, 10μm. (b) Urine albumin/creatinine 566 
ratio (ACR) of NPHS1-rtTA/TRE-APOL1-G0 (n = 11), NPHS1-rtTA/TRE-APOL1-G1 (n = 11), 567 
NPHS1-rtTA/TRE-APOL1-G2 (n = 12) mice. Single transgenic littermates served as controls (ctl) (n 568 
= 8, 6, 6 for G0, G1 and G2, respectively). Statistics was calculated by Student’s t-test, P = 0.0154 569 
(G0 vs. G1), P=0.0077 (G0 vs. G2). (c) Serum blood urea nitrogen (BUN) and creatinine levels of 570 
control (CTL) (n = 6) and NPHS1-rtTA/TRE-APOL1-G2 (n = 4) mice on doxycycline diet for 12-19 571 
days. Student’s t -test, P = 0.0042 (BUN), P = 0.0279 (creatinine). The data are presented as means 572 
± s.d. (d) Representative PAS-stained kidney images of NPHS1-rtTA/TRE-APOL1-G0, NPHS1-573 
rtTA/TRE-APOL1-G1 and NPHS1-rtTA/TRE-APOL1-G2 mice. The bottom images are higher 574 
magnifications of the boxed regions in the top images. (n > 5 per line) Scale bars: upper panels: 575 
20μm; lower panels: 10μm. (e) Quantification of the histological findings of NPHS1-rtTA/TRE-576 
APOL1-G0 (n = 12), NPHS1-rtTA/TRE-APOL1-G1 (n = 12), NPHS1-rtTA/TRE-APOL1-G2 (n = 577 
7) mice. Student’s t-test, P = 0.0087 (G0 vs. G1), P = 0.0048 (G0 vs. G2). (f) Representative 578 
transmission electron micrographs (TEM) of NPHS1-rtTA/TRE-APOL1-G0/G1/G2 mice. (n = 26, 579 
74, 54 for G0, G1, G2 mice, respectively) Scale bar: 500nm. (g) Differentially expressed pathways 580 
by RNAsequencing identified using gene set enrichment analysis. Y-axis log (p) of the false 581 
discovery rate (FWER: family-wise error rate). (h) Heatmap analysis of mouse orthologs of Ubd, 582 
Cxcl9, Cxcl1 and Muc13, previously reported to be differentially expressed in APOL1 high vs. low 583 
risk allele nephrotic syndrome subjects. Higher transcript levels are shown in red, while lower in 584 
green.  585 
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 586 
Figure 2 APOL1 risk variant-induced phenotype is cell type- and dose-dependent and likely 587 
reversible. (a) Western blot showing APOL1 and tubulin levels in kidneys of NPHS1-rtTA/TRE-588 
APOL1 transgenic mice on doxycycline for 3 (G1 and G2) to 17 (G0) weeks. (b) Left panel: Mice 589 
were matched for APOL1 transcript levels in NPHS1-rtTA/TRE-APOL1-G0/G1/G2 transgenic mice 590 
Right panel: urine albumin/creatinine ratio (ACR) of NPHS1-rtTA/TRE-APOL1-G0/G1/G2 591 
transgenic mice after doxycycline diet for 3-6 weeks. (n = 5 per group). Data are presented as means 592 
± s.e.m. and Student’s t-test, P = 0.0029 (G0 vs. G1), P = 0.00612 (G0 vs. G2). (c) Cell toxicity 593 
(measured by the ratio of dead to viable cells) assay in TRE-GFP/APOL1-G0, G1 or G2 transiently 594 
transfected HEK293 cells and normalized to GFP (APOL1) levels. Grey bars represent no 595 
doxycycline treated and black (in CTL or G0) or white bars (in G1 or G2) represent doxycycline 596 
treated cells. Student’s t-test, P = 0.0031 (G0 vs. G1), P = 0.016 (G0 vs. G2). (d) Violin plots of 597 
eGFR (right graph) in a group of low risk (LR) and high-risk (HR) APOL1 genotype patients 598 
matched by APOL1 expression level (left graph) (FPKM: fragments per kilobase million) and age, 599 
gender and other sequencing parameters (1:3=HR (n = 11) : LR (n = 33)). Significance was 600 
calculated by conditional logistic regression P = 0.032 (right graph). (e) Correlation between APOL1 601 
transcript levels (by qRT-PCR) and albumin/creatinine ratio for NPHS1-rtTA/TRE-APOL1-G0, G1 602 
or G2 mice. n = 15 per group. The red, white and black diamonds in the graph for the G2 allele 603 
represent 3 mice of varying expression of this risk allele and used for analysis in f. (f) Representative 604 
PAS-stained kidney images of NPHS1-rtTA/TRE-APOL1-G2 with increasing levels of APOL1 605 
transcript. The diamonds represent the same 3 mice shown in e for the G2 group. (n > 5 per line) (g) 606 
APOL1 cell toxicity in TRE-GFP/APOL1-G0, G1 or G2 transiently transfected HEK293 cells 607 
treated with different concentrations of doxycycline (increasing APOL1 expression), cell toxicity 608 
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was normalized to GFP (APOL1) expression. (h) Violin plots of glomerular APOL1 transcript level 609 
measured by RNA sequencing on microdissected glomeruli from 286 human kidney samples in 610 
control (GFR> 60mL/min/1.73m2) and CKD (GFR<60ml/min/1.73m2) patients. Student’s t-test, P = 611 
0.000283. (i) Coomassie gels of urine samples from mice that were placed on doxycycline food for 612 
14 days and then either kept on doxycycline food (on group) or taken doxycycline diet off (off 613 
group). Urine samples were taken from day 0, 14, 21 and 31 following initiation of doxycycline food.  614 
Quantifications of albumin gel images are shown at the bottom. Intensity of the albumin of Day 21 615 
and 31 were both normalized to that of day 14 (the time of splitting up the groups). All data are 616 
presented as means ± s.d. (unless otherwise indicated).  617 
 618 
 619 
Figure 3 APOL1 risk allele cells show increased accumulation of intracellular vesicles, mainly 620 
late endosomes/autophagosomes. (a) Immunogold electron microscopy (EM) of APOL1 in human 621 
kidney podocytes. APOL1 localizes to plasma membrane (red circles) and intracellular vesicles 622 
(blue arrows). Scale bar, 200nm. (b) Double immunofluorescence micrographs of cultured human 623 
podocytes with APOL1 (red) and intracellular organelle markers (green) (EEA1-early endosome, 624 
Rab7-late endosome, Rab11-recycle endosome, LC3-autophagic vacuoles, LAMP2-lysosomes). Scar 625 
bar, 11μm. (c) Quantification of colocalization correlation using Pearson r correlation through 626 
ImageJ coloc2 function. n = 5 separate experiments, 3-10 cells for each genotype were analyzed. 627 
Data are presented as means ± s.e.m. (d) Representative frame from the supplementary video 1 of 628 
spinning disk confocal microscopy analysis of GFP-APOL1 (green) and RFP-Rab7 (late endosome) 629 
(red) in transfected HEK293 cells. Arrowheads, overlapping puncta of GFP-APOL1 and RFP-Rab7. 630 
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Scale bar, 5μm. (e-f) Representative fluorescence images of confocal microscopy analysis of 631 
endogenous. (e) Rab7 and (f) LC3 immunofluorescence stain in cultured low risk genotype (G0/G0) 632 
and high risk genotype (G1/G2) human podocytes and quantification showing increased stain in 633 
G1/G2 cells. n = 5 separate experiments, 3-10 cells for each genotype were analyzed. Scale bars, 634 
11μm. (g) Representative transmission electron micrographs from control, TRE-APOL1-G0, TRE-635 
APOL1-G1 and TRE-APOL1-G2 transfected HEK293 cells. Examples of autophagy-related 636 
compartments include: **(two black asterisks): Late endosomes/MVB (MVB), *(one black 637 
asterisk): autophagosomes (APG), ** (two white asterisks): autolysosomes (AUT), * (one white 638 
asterisk): amphisomes (AMP). Scale bars, 0.5μm. (h) Quantification showing the number of each 639 
type of vesicle per section. n = 7 analyzed sections. Data are presented as means ± s.e.m. and 640 
Student’s t-test, P = 0.032, 0.0057, 0.011 for G0, G1, G2 comparing to control (AUT); while P = 641 
0.024,0.00027, 0.00903 for G0, G1, G2 comparing control (AMP). (i) Quantification showing the 642 
relative percentage of each compartment. n = 7  analyzed sections. Data are presented as means ± 643 
s.e.m. and Student’s t-test,  P = 0.0064 (G2 vs. CTL, APG), 0.0068 and 0.0.01005 (G0 and G2, 644 
respectively, vs. CTL, AUT), 0.034 and 0.00044 (G0 and G2, respectively, vs. CTL, AMP). (j) 645 
Representative frames from the supplementary videos 1 and 2 of spinning disk confocal microscopy 646 
analysis of GFP-APOL1-G0 or GFP-APOL1-G2 (green) and RFP-Rab7 or RFP-Rab11 (red) in 647 
transfected HEK293 cells. Scale bar, 5 μm. All data are presented as means ± s.d. (unless otherwise 648 
indicated). 649 
 650 
Figure 4 Risk variants of APOL1 obstruct autophagy flux. (a) Representative Western blot 651 
analysis and (b) quantification of LC3 and GFP in TRE-APOL1 transfected HEK293 cells under fed 652 
(F), starved (S) and starved+chloroquine treatment (SCQ) conditions. Top panel shows LC3I and 653 
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LC3II bands on the same gel. Due to high LC3I content in the cells, different exposure times of the 654 
individual rows of LCI and LCII (see solid and dashed arrowed lines, respectively, pointing to the 655 
lower panels) were utilized for clear and quantifiable visibility of the bands. Data are presented as 656 
means ± s.e.m. and Student’s t-test compared to TRE-APOL1-G0 transfected cells. (c) 657 
Quantification of autophagosomes (AP) and autophagolysosomes (AL) by transmission EM and 658 
their ratio in transfected HEK293 cells. n = 35, 32, 54 and 42 cells for control, G0, G1 and G2 659 
transfected cells were analyzed, respectively. All data are presented as means ± s.e.m. and Student’s 660 
t-test,  P = 0.0013 (left panel), 0.025 (right panel) compare to non-transfected (CTL) + TRE-661 
APOL1-G0 transfected cells. (d,e) LC3 staining of low risk (G0/G0) and high-risk (compound 662 
heterozygous G1/G2) genotype human podocytes under fed (F), starved (S) and starved plus 663 
chloroquine (SCQ) conditions (d) and quantification of this data (e). Scale bars, 11μm. n = 3, 9-20 664 
cells were analyzed per condition. Data are presented as means ± s.e.m. and Student’s t-test, P = 665 
0.0462 (left panel), 0.0104 (right panel) compared to low risk genotype (G0/G0) podocytes. 666 
 667 
Figure 5 APOL1 risk variants induce inflammatory cell death (pyroptosis) in cells. (a) 668 
Representative Western blot analysis of caspase3 (Casp3) and cleaved caspase3 (cCasp3) following 669 
transient transfection with TRE-APOL1-G0/G1/G2. UV exposure served as apoptosis positive 670 
control. n = 5. (b) Representative Western blot analysis of caspase1 (Casp1) and cleaved caspase1 671 
(cCasp1) following transient transfection of TRE-APOL1-G0/G1/G2. GFP served as an APOL1 672 
expression reference, α-tubulin as loading control and LPS as pyroptosis positive control. Western 673 
blot analysis of mature IL1β in medium from the same transfected HeLa cells. (c) Cell toxicity 674 
(measured by propidium iodide staining) in stably transfected TRE-GFP/APOL1-G1 HEK293 cells, 675 
with (APOL1) or without (CTL) doxycycline and in the presence of the indicated caspase1 inhibitors 676 
  30
(concentration see Methods). Experiments were done in triplicates. Data are presented as means ± 677 
s.e.m, and Student’s t-test, P = 0.0015 (Ac-YVAD-CHO), 0.00018 (VX765) compared to APOL1. 678 
(d) Cell toxicity (measured by LDH release to the medium) in stably transfected TRE-GFP/APOL1-679 
G1 HEK293 cells with (APOL1) or without (CTL) doxycycline and with indicated inhibitors 680 
(concentration see Methods). A representative experiment out of three is presented; each experiment 681 
was done in triplicates. All data are presented as means ± s.e.m, and Student’s t-test, P < 0.05.  682 
 683 
Figure 6 Mice with podocyte specific APOL1 risk allele expression show increased podocyte 684 
loss, autophagy block and increased inflammatory cell death. (a) Representative 685 
immunohistochemistry images of WT1 (upper), nephrin (middle) and TUNEL staining (lower) in 686 
NPHS1-rtTA/TRE-APOL1-G0/G1/G2 mouse kidney sections. (n  > 5 per line) Scale bars, 10μm.   687 
(b) Left panel: Quantification of stained cells per glomerulus of WT1 (a podocyte marker), in 688 
transgenic mice. n = 11 analyzed images per condition .  Student’s t-test, P =0.0036 compared to 689 
NPHS1-rtTA/TRE-APOL1-G0 mice and single transgenic control mice.  Right panel: Quantification 690 
of stained cells per glomerulus of TUNEL stain from transgenic mice.  n = 12 analyzed images per 691 
condition. Student's t -test, P = 0.0011 compared to NPHS1-rtTA/TRE-APOL1-G0 mice and single 692 
transgenic control. (c) Representative transmission EM images of podocytes from transgenic mice 693 
showing increased numbers of MVB and autophagosomes. Inserts show multivesicular bodies (*) 694 
and amphisome-like structures (**). Scale bars, 500nm. (d) Quantification of autophagosomes (AP) 695 
and autolysosomes (AL) in transgenic mice. Note increased ratio of AP to AL in G1 and G2 mice 696 
compared to G0 mice. n > 50 analyzed organelles per each condition. Data are presented as means ± 697 
s.e.m. and Student’s t -test, P = 8.1816e-07 (left panel), 0.037 (right panel) compared to NPHS1-698 
rtTA/TRE-APOL1-G0 mice. (e) Representative immunohistochemistry images of LC3II from 699 
transgenic mice. Note the increased podocyte stain in G1 and G2 mice compared to G0 mice, 700 
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suggesting increase in autophagic vacuole content. (n > 5 per line) Scale bars, 10μm.  (f-h) 701 
Representative immunohistochemistry images of IL1β, NLRP3 and caspase1, showing increased 702 
stain of pyroptosis proteins in podocytes of G1 and G2 mice, compared to G0 mice. (n > 5 per line) 703 
Scale bars, 10 μm. (j) Representative immunohistochemistry images of cleaved caspase3 from 704 
transgenic mice. Note lack of detectable stain, indicating apoptosis is not significantly induced in 705 
transgenic mice. (n > 5 per line) Scale bars, 10 μm. (i) Differential expression of a set of genes by 706 
RNA-seq analysis in kidneys of NPHS1-rtTA/TRE-APOL1-G0/G1/G2 mice. Single transgenic 707 
littermates and NPHS1-rtTA/TRE-APOL1-G0 are controls.  708 
709 
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Online Methods 710 
Antibodies and reagents 711 
The following primary antibodies were used: GFP (immunohistochemistry (IHC), 712 
Clontech #632380, 1:500; western blot (WB), 1:3000), WT1 (IHC, Santa Cruz #M3561, 1:40), 713 
EEA1 (immunofluorescence (IF), BD transduction #610456, 1:100), Vamp8 (IF, Sigma 714 
#SAB1409943, 1:100), Rab7 (IF, Sigma #R8779, 1:100), Rab11 (IF, BD transduction #610656 715 
1:100), LAMP2 (IF, BD transduction #555803, 1:100), LC3II (WB, Sigma #L7543, 1:1000; IF, 716 
cell signaling #27755, 1:100), STX17 (IF, Sigma #HPA001204, 1:100), APOL1 (WB, Sigma 717 
#HPA018885, 1:1000; IF, Sigma, 1:100), GM130 (IF, BD transduction #610822, 1:100), 718 
calnexin (IF, BD transduction #610523, 1:200), perilipin2 (IF, Sigma #611042, 1:500), Nephrin 719 
(IF, Fitzgerald Industries Intl Inc #20R-NP002, 1:100 ), cleaved-Caspase-3 (WB and IHC, cell 720 
signaling #9664, 1:1000), Caspase-1 (WB, Santa Cruz #SC515, 1:1000; IHC, Thermo Fisher 721 
#PA5-38099, 1:100), IL1β (WB, R&D #AF-201-NA, 1:1000; IHC, cell signaling #12242S, 1:100), 722 
NLRP3 (IHC, Novus #NBP2-12446, 1:100), α-tubulin (WB, Sigma #T6199, 1:3000). The 723 
following experimental materials were used: RPMI 1640 (Cellgro), MEM eagle (Sigma), DMEM 724 
1X (Cellgro), FBS (Atlanta Biologicals), Tet system approved FBS (Clontech), Penicillin-725 
Streptomycin (Cellgro), insulin transferrin selenium (ITS) (Cellgro), L-glutamine (Cellgro), 726 
Doxycycline (Clontech), Digitonin (CalBioChem). The following inhibitors were used: Ac-YVAD-727 
CHO (Cayman Chemicals, 50μM), VX765 (Toronto Research Chemicals, 10μM), CRID3 (Tocris 728 
bioscience, 50μM), Parthenolide (ENZO, 100μM), rapamycin (LC laboratories, 1ng/ml), 729 
STF62247 (Cayman Chemicals, 1.25μM).  730 
 731 
Transgenic mice 732 
TRE-APOL1 mice were generated by cloning APOL1 (G0/G1/G2) cDNA into the pBI-733 
EGFP vector containing tetracycline response element (TRE). The transgenic construct was 734 
injected into FVB/N oocytes. Transgenic mice were identified by genomic PCR analysis using 735 
transgene (APOL1 and GFP) specific primers. We detected transgene integration in more than 736 
10 founder lines for each allele. We then characterized 6 founders for G0, 8 for G1 and 4 for G2 737 
by mating them with nephrin and Pax8 rtTA animals. Transgene expression was induced by 738 
doxycycline containing food (200mg/kg, BioServ). No blinding or randomization was used 739 
during animal handling. NPHS1rtTA transgenic mice were generated by Jeffrey Miner45. The 740 
Pax8rtTA mice were purchased from Jackson Laboratories (007176). Animal studies were 741 
approved by the Animal Care Committee of the University of Pennsylvania. 742 
 743 
Phenotype analysis  744 
Urine albumin and creatinine were determined using mouse albumin specific ELISA 745 
(Albuwell M kit, Exocell and Bethyl Laboratories) and creatinine reagent (Sciteck Diagnostics), 746 
per manufacturer’s protocol. 747 
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For NPHS1-rtTA/TRE-APOL1G2/WT mice, the serum creatinine and BUN were 748 
measured by i-STAT CHEM8+ Cartridge according to manufacturer’s instructions (Abbott).  749 
 For Pax8-rtTA/TRE-APOL1 transgenic mice, serum creatinine and BUN were 750 
determined by Mouse Creatinine Kit (Crystal Chem) and TRACE DMA Urea kit (Thermo 751 
Electron Corporation), respectively, according to manufacturers’ instructions. 752 
Histological analysis was performed on formalin fixed paraffin embedded kidney 753 
sections stained by PAS (periodic acid Schiff). 754 
 755 
Electron microscopy 756 
Tissues for electron microscopic examination were fixed with 2.5% glutaraldehyde, 2.0% 757 
paraformaldehyde in 0.1M sodium cacodylate buffer, pH7.4, overnight at 4oC.   Samples were post-758 
fixed in 2.0% osmium tetroxide. The tissue was infiltrated and embedded in EMbed-812 (Electron 759 
Microscopy Sciences, Fort Washington, PA).  Thin sections were stained with uranyl acetate and 760 
lead citrate and examined with a JEOL 1010 electron microscope fitted with a Hamamatsu digital 761 
camera and AMT Advantage image capture software. Morphometric analysis of micrographs was 762 
performed using conventional criteria46. Scoring of vesicular compartments was performed blinded. 763 
For each group 32-54 sections and 100-117 compartments were examined. Type of compartment 764 
was determined by the following criteria: autophagosomes were identified as ribosome-free double 765 
or partially double membrane vesicles with identified cargo or content of s comparable density to the 766 
surrounding cytosol; autolysosomes were identified as single membrane vesicles with content of 767 
lower density than the surrounding cytosol and cargo suggestive of breakdown; late 768 
endosome/multivesicular bodies were identified as single membrane vesicles containing 769 
homogenous single membrane vesicles in their low density lumen; amphisomes were defined using 770 
the same criteria of  late endosome/multivesicular bodies, only containing cytosolic material of 771 
different density in their lumen. The membrane of amphisomes often presented invaginating vesicles 772 
representing multivesicular body formation. Immunogold studies were performed on human samples 773 
using APOL1 (Sigma #HPA018885) antibody. 774 
 775 
Western blotting 776 
Whole kidney was removed from NPHS1-rtTA/TRE-APOL1 or Pax8-rtTA/TRE-APOL1 777 
transgenic mice and subject to western blot analysis. Briefly, kidney lysates were homogenized 778 
in 1% SDS lysis buffer (1% SDS, 1% Triton x-100, 50mM Tris pH7.4, 150mM NaCl, 1mM EDTA) 779 
containing protease inhibitor cocktail (Complete Mini, Roche). Equal amount of total protein 780 
(35ug) were resolved on a 10% gels, transferred to a polyvinylidene difluoride membranes, 781 
blocked with 5% non fat milk in TBS-tween and probed with primary antibodies as described 782 
above at 4oC overnight, and proper secondary antibodies: anti-rabbit (Cell Signaling, 1:3000) 783 
and anti-mouse (Cell Signaling, 1:3000) IgG horseradish peroxidase (HRP) and donkey anti-784 
goat IgG HRP (Santa Cruz, 1:3000). Blots were detected by enhanced chemiluminescence 785 
(Western Lightning-ECL, Thermo Scientific) or Pierce ECL (BioRad). 786 
HeLa Tet-On 3G cells (Clontech), transfected HEK293 cells or GFP-TRE-G1APOL1 787 
HEK293, urinary podocytes were cultured at 37oC in appropriate medium as described above 788 
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in the presence of 5% CO2. Cell lysates were prepared with 1% SDS lysis buffer as above. 789 
Proteins were resolved on a 10-15% gradient gels, and then follow the subsequent western 790 
blot procedure as above.  791 
 792 
Podocyte, HEK293 and HeLa cell culture and transfection 793 
Transformed human podocytes were generated as previously described47. Subjects 794 
gave informed consent for genetic studies and for podocyte culture under protocols approved 795 
by the NIDDK Institutional Review Board. Human urinary podocytes were cultured in RPMI 796 
1640 supplemented with 10% fetal bovine serum, 1% insulin-transferrin-selenium and 1% 797 
penicillin-streptomycin at 33oC. Differentiation was induced when cells were approximately 798 
60-70% confluent by thermoshifting to 37oC for 14d.  799 
HEK293 Tet-On 3G cells (Clontech) were cultured in Eagle MEM with 10% Tet system 800 
approved fetal bovine serum (FBS), 10% L-glutamine and 1% penicillin-streptomycin. Cells 801 
were transfected with the TRE-GFP/APOL1 construct using Xfect kit (Clontech) per 802 
manufacturer’s protocol. On the following day, transfected cells were treated with doxycycline 803 
to induce APOL1 expression.  804 
HeLa Tet-On 3G cells (Clontech) were cultured at 37oC in complete DMEM 1X with 10% 805 
tet system approved FBS and penicillin-streptomycin. Cells were transfected using Xfect 806 
according to manufacturer’s protocol. APOL1 expression was induced by doxycycline. Cells 807 
were incubated at 37oC for 24-48h after doxycycline addition before subjected to further 808 
analysis.  809 
Stably transfected (GFP-TRE-G1APOL1) HEK293 cells were generated by puromycin 810 
selection followed by FACS sorting (GFP) and cylinder cloning. We have confirmed doxycycline 811 
inducible APOL1 expression on Western blots. 812 
 813 
Cytotoxicity assays 814 
HEK293 3G cells or G1APOL1 were plated in 96-well plate. Transfection of HEK293 815 
cells with APOL1 plasmid was carried out as described above and doxycycline was added for 816 
12hr. The plate was read using SpectraMax for 485ex-535em for GFP signal. Then the medium 817 
was carefully removed and cells were incubated with HBSS (with Ca2+ and Mg2+) and 5μM 818 
propidium iodide (PI) at 37oC for 30 min. The plate then was read using SpectraMax for 530ex 819 
– 620em for dead cells. Without removing HBSS+PI, cells were incubated with equal volume of 820 
CellTiter Glo 2.0 reagent (Promega) at room temp for 10 min. Finally, the plate was read using 821 
SpectraMax for luminescence, which indicated live cell count. The ratio between dead cell 822 
reading, live cell and GFP (APOL1 expression) reading was calculated, unless otherwise 823 
indicated. 824 
LDH release test was preformed using CytoTox 96® Non-Radioactive Cytotoxicity 825 
Assay (Promega). Transfected Hela cells or GFP-TRE-G1APOL1 HEK293 cells were plated as 826 
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described above and treated with or without doxycycline and with or without inhibitors for 8-827 
24 h. Medium was collected in triplicates, spun down and incubated in a 96 well plate with the 828 
CytoTox reagent for 20-30 min. After addition of stop solution, the absorbance signal was 829 
measured at 490nm in a plate reader. 830 
 831 
RNAseq; Mouse kidneys 832 
Total RNA of transgenic and control mice kidneys was isolated using RNeasy Mini Kit 833 
(Qiagen). RNA quality was assessed with the Agilent Bioanalyzer 2100 and RIN scores above 7 834 
were used. Libraries were prepared using the Illumina TruSeq RNA Preparation Kit. Samples 835 
were sequenced using Illumina HiSeq for single-end 100bp. Trimmed reads were aligned to 836 
the Gencode mouse genome (GRCm38) with STAR-2.4.1d. The readcount of each sample was 837 
obtained using HTSeq-0.6.1 (htseq-count) and then tested with DESeq2 for differential gene 838 
expression. Top differentially regulated pathways were determined using GSEA and KEGG 839 
pathway analysis software.  840 
 841 
RNAseq; Human kidneys 842 
Kidney samples were obtained from routine surgical nephrectomies. Samples were 843 
deidentified and clinical information was collected via an honest broker. Pathology 844 
examination was performed by local nephropathologist. The study was approved by the 845 
institutional review board (IRBs) of the University of Pennsylvania. The kidney tissue was 846 
immediately placed and stored in RNAlater (Ambion) according to manufacturer’s instruction. 847 
The tissue was manually microdissected under a microscope in RNAlater for glomerular and 848 
tubular compartments. Dissected glomerular tissue was homogenized, and RNA prepared 849 
using RNAeasy mini columns (Qiagen, Valencia, CA) according to manufacturer’s instructions. 850 
RNA quality and quantity were determined as described above. RNA library preparation, 851 
sequencing and analysis were performed as described above. Reads were mapped to the 852 
reference genomes (Gencode human genome (GRCh37)) using Spliced Transcripts Alignment 853 
to a Reference (STAR). 854 
 855 
Reversibility study 856 
 NPHS1-rtTA/TRE-APOL1-G2 mice were placed on doxycycline diet at 3-9 weeks of age 857 
for 14 days. Then the mice were separated into two groups. One was continuing on 858 
doxycycline diet and the other one was fed normal chow diet. The urine samples from each 859 
mouse were collected twice a week. Urinary albumin levels on day 7 (day 21 total ) and day 17 860 
(day 31 total) after separating were monitored by SDS-PAGE and Coomassie stain.  861 
 862 
 863 
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Immunohistochemistry, immunofluorescence and TUNEL 864 
For Immunohistochemistry, sections were deparaffinized, hydrated in ethyl alcohol and 865 
washed in tap water. Antigen retrieval was carried out in 0.4% pepsin (WT1) or TRIS-EDTA, 866 
pH 9.0 (LC3II, EGFP) in 37oC incubator for 10 min; or by boiling in sodium citrate pH6 for 10 867 
min (caspase1, IL1β, NLRP3, c-casp3). Endogenous peroxidase activity was blocked in 3% 868 
H2O2 for 10 min. Endogenous biotin was blocked with avidin/biotin blocking kit (Vector Labs). 869 
Sections were blocked in 3% BSA (WT1), MOM kit blocking reagent (Vector Labs) (EGFP, IL1β) 870 
or Vectastain rabbit kit (Vector Labs) (caspase1, NLRP3, LC3II) for 1 hour at room 871 
temperature and incubated overnight at 40C with primary antibody and at room temperature 872 
for 30 min with secondary antibody. Staining was visualized using peroxidase-conjugated 873 
antibodies using either Vectastain Elite kit or MOM kit, and 3,3-diaminobenzidine (DAB), as 874 
per the manufacturer's protocol (Vector Labs). For tissue immunofluorescence, 4μm thick, 875 
O.C.T. Compound (Sakura) embedded cryosections were fixed in formalin, and then blocked 876 
and probed as described above. For cell immunofluorescence, cells were cultured on cover 877 
slips, fixed in 4% paraformaldehyde, permeabilized with 0.003% digitonin and blocked with 878 
3%BSA. Cells were incubated with primary antibody for 1 hour and with secondary conjugated 879 
antibody (Alexa Fluor 555 donkey anti rabbit or Alexa Fluor 665 goat anti mouse IgG 880 
antibodies, Life Technologies, 1:500) for 30 min in room temperature. For TUNEL stain, 881 
sections were processed as described above for IHC and labeled with TdT using the ApopTag 882 
peroxidase in situ apoptosis detection kit (Millipore #S7100). Staining was visualized using 883 
DAB. 884 
 885 
Endocytosis 886 
Doxycycline-treated transfected HEK293 cells were incubated with 75 μM Alexa647 887 
dextran (an endocytosis marker) and with 75 μM pHRodo Red Dextran (a pH sensitive 888 
endosomal marker) (Life technologies) for 16 h and then medium was changed to dextran-free 889 
medium with doxycycline for an 8h chase period. Hoechst dye was added and cells were 890 
imaged using Leica confocal microscopy. Dextran loading and imaging was done after changing 891 
medium to Live Cell Imaging Solution (Life Technologies). Images were quantified over whole 892 
cells using imageJ and normalized to background. A minimum of 20 cells were analyzed for 893 
each group in each experiment. 894 
 895 
LysoTracker labeling 896 
Doxycycline-treated transfected HEK293 cells or human urinary podocytes were 897 
incubated with 50 nM LysoTracker Red DND-99 reagent (Thermo Fisher Scientific) for 2 h and 898 
then medium was changed and cells were visualized using a Leica confocal microscope. A 899 
minimum of 20 cells were analyzed for each group. 900 
 901 
Spinning disc confocal microscopy 902 
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Live cell imaging were performed as described previously48. Briefly, GFP-APOL1, or 903 
GFP-APOL1 D388, and mRFP-Rab7 (Addgene), or DsRed-Rab11 (Addgene) tagged proteins 904 
were coexpressed in Cos7 cells by electroporation (Gene Pulser II (Bio-Rad)). Transfected cells 905 
were seeded in glass-bottomed 35-mm dishes (no. 1.5 thickness; MatTek) and imaged 18 h 906 
later. Before imaging, medium was replaced with an imaging buffer (containing 136 mM NaCl, 907 
2.5 mM KCl, 2 mM CaCl2, 1.3 mM MgCl2, and 10 mM HEPES [pH 7.4]). Cells were imaged using 908 
an Andor spinning confocal microscope with ×60 oil immersion objectives. 909 
 910 
Statistical analyses 911 
Differences between two groups were analyzed using  Student’s 2-tailed t-test assuming 912 
unequal variance. Differences between more than two groups were analyzed using one-way 913 
ANOVA test.  All data are presented as the means ± s.d., unless otherwise indicated. P < 0.05 914 
was considered to be significant.  n.s., P > 0.05. We did not perform analyses to predetermine 915 
sample sizes. Rather, the sample sizes were chosen empirically based on our previous 916 
experiences in the calculation of experimental variability. The numbers of animals used are 917 
described in the corresponding figure legends. All experiments were done with at least three 918 
biological replicates. No animals or samples were excluded from the analysis.  919 
 920 
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